Artimplant AB (STO:ARTIB):
-- Net revenue for the third quarter amounted to SEK 5.1 million (5.5) and for January-September SEK 14.9 million (18.2).
-- The net loss for the third quarter totaled SEK 5.2 million (4.7) and for January-September SEK 15.0 million (13.2).
-- Earnings per stock unit for the third quarter amounted to SEK -0.09 (-0.08) and for January-September SEK -0.25 (-0.22).
-- Artimplant's own sales continued to increase and were equivalent to 65% (40) of product sales for the third quarter and 59% (30) for January-September.
-- Artimplant's own sales in the USA have tripled at the same time that revenue from license sales halved compared with January-September 2009.
-- Artimplant's strategy has been focused on marketing with increased intensity in own sales in the USA.
-- Artimplant has implemented staff cutbacks equivalent to an annual saving of approximately SEK 5 million once the periods of notice have come to an end.
-- Study data has been presented which supports the use of Artelon® in a number of treatment applications.
Events after the period-end
-- Artimplant's rights issue was oversubscribed by 89% and, as planned, has generated capital input for the Company of approximately SEK 38.5 million before issue costs.
-- The issue will increase the number of Series B stocks by 59,244,790, from 58,669,790 to 117,914,580. The number of Series A stocks remains unchanged at 575,000. The total number of stocks after the issue is thus 118,489,580.
-- The total number of votes following the issue is 123,664,580.